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ABSTRACT 
People with diabetes display biomechanical gait alterations compared to controls 
and have a higher metabolic cost of walking (CoW), but it remains unknown whether 
differences in the vertical displacement of the body centre of mass (CoM) may play a 
role in this higher CoW. The aim of this study was to investigate vertical CoM 
displacement (and step length as a potential underpinning factor) as an explanatory 
factor in the previously observed increased CoW with diabetes. Thirty-one non-
diabetic controls (Ctrl); 22 diabetic patients without peripheral neuropathy (DM) and 
14 patients with moderate/severe Diabetic Peripheral Neuropathy (DPN), underwent 
gait analysis using a motion analysis system and force plates while walking at a 
range of matched speeds between 0.6 and 1.6 m/s. Vertical displacement of the 
CoM was measured over the gait cycle, and was not different in either diabetes 
patients with or without diabetic peripheral neuropathy compared to controls across 
the range of matched  walking speeds examined (at 1m/s: Ctrl: 5.59 (SD: 1.6), DM: 
5.41 (1.63), DPN: 4.91 (1.66) cm; p>0.05). The DPN group displayed significantly 
shorter steps (at 1m/s: Ctrl: 69, DM: 67, DPN: 64 cm; p>0.05) and higher cadence 
(at 1m/s: Ctrl: 117 (SD1.12), DM: 119 (1.08), DPN: 122 (1.25) steps per minute; 
p>0.05) across all walking speeds compared to controls. 
The vertical CoM displacement is therefore unlikely to be a factor in itself that 
contributes towards the higher CoW observed recently in people with diabetic 
neuropathy. The higher CoW in patients with diabetes may not be explained by the 
CoM displacement, but rather may be more related to shorter step lengths, 
increased cadence and the associated increased internal work and higher muscle 
forces developed by walking with more flexed joints. 
Keywords: biomechanics, diabetes, lower limbs, centre of mass. 
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INTRODUCTION 
Diabetes is a global epidemic with significant morbidity and particularly common with 
increasing age (International Diabetes Federation, 2013). Diabetes is associated 
with a range of serious complications that result in reduced quality of life and 
premature mortality. Diabetic peripheral neuropathy (DPN) is one of the most severe 
complications of diabetes, occurring in 30–50% of all diabetic patients (Cappozzo, 
1981). The main cause is neurovascular alterations to the nerve fibres and blood 
vessels supplying the nerve endings, resulting in reduced or absent nerve 
conduction (Diabetes UK: Diabetes in the UK 2011/12: Key Statistics on Diabetes. 
2014.). The European association for the study of diabetes defines DPN as “the 
presence of symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after the exclusion of other causes” (Boulton, 2005). DPN-related changes 
in the lower limbs lead to functional gait adaptations including taking shorter steps, 
having a higher cadence but slower self-selected and maximum walking speed 
(Brown et al., 2014; Chiles et al., 2014; Ko et al., 2011; Menz et al., 2004; Raspovic, 
2013; Sawacha et al., 2009). Consistently smaller ranges of motion at the ankle, 
knee and hip in the DPN group have been reported from a range of studies and likely 
underlies the shorter step length reported in diabetes patients (Abate et al., 2012; 
Gome et al., 2001; Martinelli et al., 2013; Raspovic, 2013; Sacco, 2002). Other major 
gait adaptations include reduced range of joint movement (Andersen, 2012) and 
reduced muscle strength and power characteristics (Brown et al., 2014).  
We have recently shown how the metabolic cost of walking (CoW) is higher in 
people with diabetes and particularly in those with DPN compared to controls 
(Petrovic et al., 2016). During walking, mechanical work is done to continuously raise 
and lower the body centre of mass (CoM), which requires metabolic energy 
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expenditure. The CoM in the human body moves like an inverted pendulum during 
walking, with the pendulum action conserving mechanical energy (Alexander, 1991). 
More specifically, by keeping the knee relatively straight during the single leg stance 
phase of gait, giving rise to the arc of the CoM, the leg supports body mass with 
relatively little muscular force. 
Like an inverted pendulum, the CoM rises/decelerates in the first half of the stance 
phase and then falls/accelerates during the second half of the stance phase 
(Candrilli et al., 2007; Lamoreux, 1972; Lee and Farley, 1998, Thorstensson and 
Roberthson, 1987). Consequently, in the first half of the stance phase, kinetic energy 
is converted into gravitational potential energy (Cavagna et al., 1976; Cavagna and 
Franzetti, 1986), whereas in the second half of the stance phase, the opposite 
conversion occurs. Over the gait cycle, the CoM has a sinusoidal pattern in the 
vertical direction with two peaks occurring. The first vertical peak of the CoM occurs 
around 30% of the gait cycle during single-limb stance as the CoM is ‘vaulted’ over 
the straight stance limb in an inverted pendulum manner, while the second peak 
occurs around 80% of the gait cycle during the terminal mid-stance phase.  
Increasing the CoM displacement in a type of up and down ‘bobbing’ action leads to 
an increase in the CoW compared to a normal gait (Neptune et al., 2004; Massaad 
et al., 2007). Equally, if gait is manipulated to minimise or eliminate any vertical 
displacement of the CoM by walking in a ‘crouched’ style with very flexed limbs, 
there is an increase in the CoW compared to normal gait (Ortega et al., 2007; 
Massaad et al., 2007; Gordon et al., 2009). Hence, there appears to be an ‘optimum’ 
vertical displacement for the CoM in terms of its effect on the metabolic CoW, where 
deviations from this optimum seem inefficient in terms of energy cost.  
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Stride length also seems intrinsically linked to the CoM vertical displacement and the 
associated CoW. It has been shown that stride lengths greater than the optimal, 
increase the CoM vertical displacement and increase the CoW, while stride lengths 
lower than the optimal, reduce the vertical displacement of the CoM, but also 
increase the CoW (Gordon et al., 2009). Since it is known that diabetes patients take 
shorter steps compared to controls, it might be hypothesised that that this would 
reduce the vertical displacement of the CoM, thereby increasing the CoW. Because 
walking speed may be a confounding factor in the relationship between step length 
and CoM displacement, in the present study we choose to compare the CoM vertical 
displacement at matched walking speeds between patients with diabetes and 
controls. Therefore, this study examined the vertical displacement of the CoM while 
walking at a range of matched speeds between 0.6 and 1.6 m/s. We hypothesised 
that diabetes patients would have a reduced vertical CoM displacement that might 
explain our recent findings of a greater CoW, with a reduced step length being a 
potential factor underpinning the suggested CoM behaviour. 
 
MATERIALS AND METHODS 
Participants 
After receiving ethical approval from all relevant bodies, 67 participants gave written 
informed consent to participate in this study. All procedures in this study complied 
with the declaration of Helsinki. All participants were allocated into one of three 
groups: patients with diabetes and moderate-severe peripheral neuropathy (DPN, 
n=14, 14 men), patients with diabetes but no peripheral neuropathy (DM, n=22, 12 
men) and healthy controls without diabetes or peripheral neuropathy (Ctrl, n=31, 19 
men). The same participant cohort was examined to establish the metabolic CoW 
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and reported in references (Petrovic et al., 2016). The CoW was significantly higher 
particularly in the DPN group compared with controls and also in the DM group 
compared with controls, across a range of matched walking speeds. 
All participants were assessed to confirm they satisfied the inclusion criteria for each 
group. Major exclusion criteria for participation in the study included peripheral 
vascular disease, musculoskeletal injury or recent surgery affecting gait, any 
amputation other than 1 or 2 lesser toes and open foot ulcer. A random blood 
glucose test was performed in the Ctrl group to confirm the absence of diabetes (<7 
mmol/l) and the below neuropathy tests conducted to confirm the absence of 
neuropathy in the Controls. The majority of the DM and the DPN patients reported 
taking insulin, cholesterol-lowering medication and diabetes medication, while from 
the whole sample (including controls) only 2 people reported smoking.  
 
Assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify peripheral neuropathy in diabetic 
patients and to confirm the absence of neuropathy in healthy controls. Peripheral 
neuropathy was assessed by using the modified Neuropathy Disability Score 
(mNDS) and the vibration perception threshold (VPT). The mNDS is a combined 
score taken from tests measuring the patient’s ability to detect temperature, pain, 
vibration and the Achilles tendon reflex (Boulton, 2005). The VPT was assessed by 
placing the probe of the biothesiometer (Biomedical Instrument Co, Newbury, OH, 
USA) on the apex of the hallux and increasing the level of vibration until detected by 
the participant. Patients were defined as having moderate-to-severe neuropathy and 
classed as DPN if in either one or both of their feet they displayed either an mNDS 
score of ≥6 or a VPT of ≥25 V (or both). 
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Gait analysis 
Participants were asked to walk along a 10-metre walkway in the gait laboratory at a 
series of standardised speeds (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s). The standardised 
walking speeds were controlled by measuring the velocity of a marker attached to 
the sacrum after each trial from the motion analysis data and providing immediate 
feedback for participants as to whether they needed to walk more quickly or more 
slowly on the next trial to achieve the required speed. The participant's starting 
position was altered by the experimenter to ensure a ‘clean’ (i.e., no overlap outside 
the force platform) foot-strike on one or two of the force platforms (positioned in the 
middle of the walkway) per walking trial without alteration to their natural gait. 
Walking trials were repeated until at least three ‘clean’ foot contacts with the force 
platforms were made with each limb, for each walking speed condition. Kinematics 
were collected at 100 Hz using a 10-camera Vicon motion capture system (Vicon, 
Oxford, UK) positioned around the 10-meter walkway, tracking a full-body modified 
Plug-In-Gait marker set consisting of 54 markers. Where possible markers were 
placed directly onto the skin; to minimise movement artefacts resulting from loose 
clothing all participants wore tight-fitting shorts and tops. All participants wore 
specialist diabetic shoes (MedSurg, Darco, Raisting, Germany) with a neutral foot-
bed (no rocker bottom outsole), ensuring the diabetic patients walked with safe, 
appropriate footwear whilst minimising the effect of footwear by standardising across 
all participants.  
 
Centre of mass displacement 
Gait variables (stride length, step length and cadence, vertical displacement of the 
CoM) were calculated from the kinematic data using Visual 3D software (C-motion 
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Inc., MD, USA). Motion data collected during gait analysis were processed, and 
Dempster’s segment parameter model (1955) was used to calculate mass 
distribution for each body segment, thereby allowing accurate calculation of the 
entire body centre of mass. The vertical displacement of the CoM was calculated as 
the maximum range of vertical displacement (minimum to maximum peak) of the 
CoM (Figure 2) during the whole gait cycle, using the mean of the three trials from 
each person. 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to assess 
between group differences. If the ANOVA was significant, a Fisher’s least significant 
difference (LSD) post-hoc test was used to test for differences between the diabetes 
groups (DM and DPN) and the control group. All values presented are means and 
standard deviation. Significance was set at p<0.05. The power analysis identified 
minimum group sizes of n=7, for an effect size 0.71 (β=0.1, α=1%). Analysis of 
covariance was used to assess the effect of body mass on CoM excursion. 
Pearson product-moment correlation coefficients were calculated at each walking 
speed (and all walking speeds combined) using data from participants in all three 
experimental groups to determine whether there was a significant correlation 
between the CoM vertical displacement and the cost of walking (previously published 
data on CoW, Petrovic et al., 2016). 
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RESULTS 
Participant characteristics  
There were significant differences between the groups in age, body mass and BMI, 
which were significantly greater in the DPN group (Table 1, p<0.01). 
 
Step length and cadence 
The DPN group displayed significantly shorter step lengths across all speeds 
compared to the Ctrl group (Table 2). The DPN group had significantly higher 
cadence across all speeds compared to the control group. 
 
Centre of mass displacement at different speeds 
Across all matched speeds there were no significant differences in the CoM vertical 
displacement between groups (Fig. 1; Table 3), neither when including a body mass 
as a covariate. 
Pearson’s correlations only reached significance at walking speeds of 0.8 and 1.6 
m/s, but the r values were consistently low across speeds ranging between -0.287 
and 0.262 (Table 4). When combining data for all participants, across all walking 
speeds Pearson’s correlation failed to reach significance, with an r value of -0.08 
(Table 4, Figure 3). 
 
DISCUSSION 
This study has shown for the first time that the vertical displacement of the CoM 
during walking is not different between diabetes patients with and without diabetic 
peripheral neuropathy compared to controls across a range of matched speeds (Fig. 
1) and is therefore unlikely to be a factor in itself that contributes towards the 
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increased CoW observed recently(Petrovic et al., 2016) on the same data set in 
people with diabetic peripheral neuropathy (at 1.2 m/s: Ctrl: 2.18 (SD: 0.67), DM: 
2.20 (0.81), DPN: 2.35 (1.76) J·kg1·m1; p>0.05). Furthermore, the relationship 
between the CoM and CoW was very weak across all walking speeds (Table 4, 
Figure 3), indicating no clear link between these two variables across participant 
groups in the present study.  
It has previously been shown that stride lengths shorter and longer than the optimum 
lead to reduced and increased CoM displacements, respectively, but increasing the 
metabolic CoW in both situations (Gordon et al., 2009). In this previous study, 
participants increased their metabolic cost when they reduced their vertical CoM 
movement by taking shorter strides. Participants also expended more metabolic 
energy when they walked with a greater stride length than their preferred stride 
length. Previous work (Donelan et al., 2002) has shown that as stride length 
increases, metabolic energy expenditure and mechanical work performed on the 
CoM also increase. This is not caused by CoM displacement per se but rather by the 
additional negative work performed to redirect the CoM velocity during step-to-step 
transitions and by positive work to restore the energy lost. Although we did find 
consistently shorter step lengths across matched walking speeds in patients with 
diabetes and particularly those with diabetic peripheral neuropathy compared to 
controls, this did not alter the vertical displacement of the CoM compared to controls 
(Fig. 1).  
The lack of effect of stride shortening on the CoM in the present study might be due 
to the fact that people with diabetes and diabetic peripheral neuropathy have 
adapted to a different optimal step length, which is consistently shorter compared to 
controls across the range of walking speeds examined. Alternatively, they could 
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have adopted a different step length based on the total metabolic CoW rather than 
the cost associated with CoM displacement. Consistent with the shorter steps taken 
by both diabetes groups compared to controls, was the higher cadence required to 
meet the prescribed matched walking speeds by the diabetes patients (Table 2). An 
increased cadence in the diabetes groups would require greater internal work from 
the muscles to move the legs during walking (Minetti et al., 1994). Although we have 
previously found (Petrovic et al, 2016) the joint work developed during a single 
stance phase to be lower in patients with diabetes and even more so in those with 
diabetic peripheral neuropathy, this would be repeated more often over a given 
distance in diabetes patients because of a higher cadence. Therefore, a higher 
cadence for any given walking speed could explain the higher CoW previously 
reported in patients with diabetes and those with diabetic peripheral neuropathy 
through greater cumulative joint work (Petrovic et al., 2016). 
In the absence of differences in the CoM vertical displacement, another possible 
explanation for the higher CoW previously reported in diabetes patients is that they 
might be producing greater muscle force without performing as much joint work per 
stance phase. This would be consistent with previous reports from walking with a 
‘crouched gait’ by excessively flexing the joints (Massaad et al., 2007; Ortega et al., 
2007). Diabetes patients were observed to walk with shorter steps, which is known to 
be achieved by greater flexion in the lower limb joints. This likely gives rise to higher 
muscle forces to sustain the more flexed joint positions as previously observed 
(Sasaki et al., 2009) and consequently a higher metabolic CoW. Therefore, the 
effective mechanical advantage (muscle force moment arm/ground reaction force 
moment arm) may be less favourable in diabetic patients (Petrovic et al., 2017), 
which would mean that more muscle force would be required to overcome the 
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moment of the ground reaction force – hence higher CoW. This factor may also 
explain why diabetes patients have adopted an “optimum” CoM displacement 
(meaning unaltered compared to controls) per stride length as a strategy to minimise 
CoW. Gordon et al. (2009) presented in their study a manipulation of step length 
above and below the optimal and found that the CoM vertical displacement 
increases and decreases over that observed at the self-selected step length. Both of 
these situations were associated with a higher metabolic CoW compared to that 
observed at self-selected step length, suggesting an optimal vertical displacement of 
the CoM where energy cost is minimised. People who are at higher risk of falls have 
been shown to take shorter steps (Karamanidis et al., 2008; Schillings et al., 2005) 
as part of a more cautious strategy to walking, which could be one of a number of 
potential factors causing them to walk with shorter steps. Another potential reason 
could relate to reduced ankle range of movement, reduced Achilles tendon 
elongation and increased Achilles tendon stiffness during walking as we have 
recently shown (Petrovic et al, 2018). 
Other factors contributing to an increased metabolic CoW in patients with diabetes 
and diabetic peripheral neuropathy could include increased muscle co-activation, 
which has been shown in older adults without diabetes (Cronin et al., 2010, Mian et 
al., 2007) and an increased Achilles tendon stiffness (Petrovic et al., 2018). Indeed, 
we have recently shown how Achilles tendon stiffness is higher in people with 
diabetes and particularly those with diabetic peripheral neuropathy compared to 
controls during walking (Petrovic et al., 2018). An increased Achilles tendon stiffness 
would reduce the elastic energy stored from this long tendon during walking, 
requiring a relatively greater energy contribution from the plantar flexor muscles, 
increasing the metabolic CoW. 
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To the best of our knowledge this is the first study that has investigated the CoM 
displacement during walking in a diabetic patient population. It could be considered 
as a limitation of the present study that body mass was significantly different 
between groups. However, the higher body mass of patients with diabetes 
(especially those with DPN) is a well-known characteristic of this population 
described in the literature (Ijzerman et al., 2011; Jor’dan et al., 2014) and is unlikely 
to have directly affected the CoM vertical displacement. If anything, it might be 
expected that increased body mass might reduce the extent to which the CoM is 
displaced, but this was not found in the present study indicating that group 
differences in body mass did not influence the present results. Although only a mean 
of 10 years difference, patients in the DPN group were significantly older than 
controls (66 to 56 years, respectively), which might be considered a confounding 
factor for some of the variables examined. 
We have shown that there are no differences in the vertical displacement of the CoM 
in patients with diabetes compared with controls when walking speed is matched and 
no relationship between the CoM vertical displacement and the CoW. The higher 
CoW in patients with diabetes may not be explained by the vertical CoM 
displacement, but rather may be more related to shorter step lengths, increased 
cadence and the associated increased internal work and higher muscles forces 
developed by walking with more flexed joints. 
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Table 1. Participant characteristics and results from neuropathy assessments. 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 56 (10) 51 (9)** 66 (14)** 
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)** 
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11) 
BMI (kg/m2) 26 (3) 28 (4) 31 (4)** 
NDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)** 
Diabetes duration (years) - 14 (12) 14 (11) 
Type 1 diabetes (n) - 7 4 
Type 2 diabetes (n) - 15 10 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and 
diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by ** (P<0.01). BMI = body mass index, 
NDS = neuropathy disability score, VPT = vibration perception threshold. Values are 
means (standard deviations). 
 
Table 2. Temporal-spatial gait parameters. 
Variable Group 
 Ctrl  DM DPN 
0.6 m/s    
Step length (m) 0.59 (0.12) 0.57 (0.12) 0.51 (0.09)** 
Cadence (steps/m) 108 (0.61) 108 (0.74) 113 (0.41)** 
0.8 m/s    
Step length (m 0.63 (0.14) 0.57 (0.12) 0.53 (0.15)** 
Cadence (steps/m) 112 (0.84) 113 (0.67) 116 (0.68)** 
1.0 m/s    
Step length (m) 0.69 (0.15) 0.67 (0.05) 0.64 (0.04)* 
Cadence (steps/m) 117 (1.12) 119 (1.08) 122 (1.25)** 
1.2 m/s    
Step length (m) 0.76 (0.11) 0.75 (0.17) 0.69 (0.07)* 
Cadence (steps/m) 124 (1.16) 125 (1.27) 128 (1.08)** 
1.4 m/s    
Step length (m) 0.79 (0.12) 0.77 (0.17) 0.71 (0.11)* 
Cadence (steps/m) 127 (1.56) 129 (1.47) 131 (1.49)** 
1.6 m/s    
Step length (m) 0.81 (0.11) 0.80 (0.04) 0.74 (0.02)* 
Cadence (steps/m) 129 (0.98) 132 (0.48) 135 (0.63)** 
Maximum walking speed (m/s) 
Step length (m) 
Cadence (steps/m) 
1.92 (0.11) 
0.85 (0.07) 
143 (1.18) 
1.88(0.16)**  
0.79 (0.06)* 
140 (1.27)* 
1.68 (0.22)** 
0.78 (0.12)** 
129 (0.98)** 
Figure
Click here to download Figure: Final figures_v06MP.docx
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and 
diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). Values are 
means (standard deviations). Gait parameters were collected on the laboratory 
walkway. 
 
Table 3. Differences in vertical displacement of the CoM in percentages. 
Walking 
speed 
Ctrl  
(cm) 
DM  
(cm) 
DPN  
(cm) 
Diff Ctrl-DM  
(%) 
Diff Ctrl-DPN 
(%) 
0.6 m/s 4.64 (1.51)  4.43 (1.52) 4.50 (1.49) -4.60 -3.00 
0.8 m/s 4.53 (1.55) 4.65 (1.56) 4.71 (1.59) 2.71 3.97 
1 m/s 5.59 (1.60) 5.41 (1.63) 4.91 (1.66) -3.25 -12.14 
1.2 m/s 6.19 (1.63) 5.77 (1.68) 4.75 (1.74) -6.78 -23.32 
1.4 m/s 6.68 (1.71) 6.13 (1.70) 6.07 (1.79) -8.23 -9.23 
1.6 m/s 7.09 (1.79) 6.73 (1.76) 7.30 (1.82) -5.01 3.03 
MAX 6.43 (1.87) 6.07 (1.85) 7.73 (1.88) -5.60 20.22 
Centre of mass (CoM) vertical displacement across walking speeds from 0.6 to 1.6 
m/s and maximum walking speed for healthy controls (Ctrl, n=31), diabetic patients 
with no neuropathy (DM, n=22) and diabetic patients with moderate/severe 
neuropathy (DPN, n=14). Values are means (standard deviations). 
 
Table 4. Bivariate correlations between vertical centre of mass displacement and 
cost of walking. 
Walking speed R value P value 
0.6 m/s -.027 .828 
0.8 m/s .262 .032 
1.0 m/s -.218 .077 
1.2 m/s -.223 .069 
1.4 m/s -.214 .082 
1.6 m/s -.287 .019 
MAX -.071 .566 
All speeds -.080 .084 
Pearson’s correlations encompassing participants in all three groups (DPN, DM and 
Ctrl, n=67) at each walking speed from 0.6 to 1.6 m/s and maximum walking speed. 
 
 Figure 1. Centre of mass (CoM) vertical (Z) displacement across walking speeds 
from 0.6 to 1.6 m/s and maximum walking speed for healthy controls (Ctrl; n=31), 
diabetic patients with no neuropathy (DM; n=22) and diabetic patients with 
moderate/severe neuropathy (DPN; n=14). Values are group means and SD; ** 
denotes significantly (P<0.01) different from the control group. 
 
Figure 2. Example trace from one participant showing the vertical displacement of 
the centre of mass over the gait cycle. The vertical displacement values reported in 
the present study reflect the minimum to maximum peak value. 
 
 Figure 3. Individual data points for all participants from all three experimental groups 
(DPN, DM and Ctrl, n=67) and at all measured walking speeds (speed from 0.6 to 
1.6 m/s and maximum walking speed). Linear trendline reflects the Pearson’s 
correlation between the two variables (centre of mass and the cost of walking). 
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ABSTRACT 
People with diabetes display biomechanical gait alterations compared to controls 
and have a higher metabolic cost of walking (CoW), but it remains unknown whether 
differences in the vertical displacement of the body centre of mass (CoM) may play a 
role in this higher CoW. The aim of this study was to investigate vertical CoM 
displacement (and step length as a potential underpinning factor) as an explanatory 
factor in the previously observed increased CoW with diabetes. Thirty-one non-
diabetic controls (Ctrl); 22 diabetic patients without peripheral neuropathy (DM) and 
14 patients with moderate/severe Diabetic Peripheral Neuropathy (DPN), underwent 
gait analysis using a motion analysis system and force plates while walking at a 
range of matched speeds between 0.6 and 1.6 m/s. Vertical displacement of the 
CoM was measured over the gait cycle, and was not different in either diabetes 
patients with or without diabetic peripheral neuropathy compared to controls across 
the range of matched  walking speeds examined (at 1m/s: Ctrl: 5.59 (SD: 1.6), DM: 
5.41 (1.63), DPN: 4.91 (1.66) cm; p>0.05). The DPN group displayed significantly 
shorter steps (at 1m/s: Ctrl: 69, DM: 67, DPN: 64 cm; p>0.05) and higher cadence 
(at 1m/s: Ctrl: 117 (SD1.12), DM: 119 (1.08), DPN: 122 (1.25) steps per minute; 
p>0.05) across all walking speeds compared to controls. 
The vertical CoM displacement is therefore unlikely to be a factor in itself that 
contributes towards the higher CoW observed recently in people with diabetic 
neuropathy. The higher CoW in patients with diabetes may not be explained by the 
CoM displacement, but rather may be more related to shorter step lengths, 
increased cadence and the associated increased internal work and higher muscle 
forces developed by walking with more flexed joints. 
Keywords: biomechanics, diabetes, lower limbs, centre of mass. 
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INTRODUCTION 
Diabetes is a global epidemic with significant morbidity and particularly common with 
increasing age (International Diabetes Federation, 2013). Diabetes is associated 
with a range of serious complications that result in reduced quality of life and 
premature mortality. Diabetic peripheral neuropathy (DPN) is one of the most severe 
complications of diabetes, occurring in 30–50% of all diabetic patients (Cappozzo, 
1981). The main cause is neurovascular alterations to the nerve fibres and blood 
vessels supplying the nerve endings, resulting in reduced or absent nerve 
conduction (Diabetes UK: Diabetes in the UK 2011/12: Key Statistics on Diabetes. 
2014.). The European association for the study of diabetes defines DPN as “the 
presence of symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after the exclusion of other causes” (Boulton, 2005). DPN-related changes 
in the lower limbs lead to functional gait adaptations including taking shorter steps, 
having a higher cadence but slower self-selected and maximum walking speed 
(Brown et al., 2014; Chiles et al., 2014; Ko et al., 2011; Menz et al., 2004; Raspovic, 
2013; Sawacha et al., 2009). Consistently smaller ranges of motion at the ankle, 
knee and hip in the DPN group have been reported from a range of studies and likely 
underlies the shorter step length reported in diabetes patients (Abate et al., 2012; 
Gome et al., 2001; Martinelli et al., 2013; Raspovic, 2013; Sacco, 2002). Other major 
gait adaptations include reduced range of joint movement (Andersen, 2012) and 
reduced muscle strength and power characteristics (Brown et al., 2014).  
We have recently shown how the metabolic cost of walking (CoW) is higher in 
people with diabetes and particularly in those with DPN compared to controls 
(Petrovic et al., 2016). During walking, mechanical work is done to continuously raise 
and lower the body centre of mass (CoM), which requires metabolic energy 
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expenditure. The CoM in the human body moves like an inverted pendulum during 
walking, with the pendulum action conserving mechanical energy (Alexander, 1991). 
More specifically, by keeping the knee relatively straight during the single leg stance 
phase of gait, giving rise to the arc of the CoM, the leg supports body mass with 
relatively little muscular force. 
Like an inverted pendulum, the CoM rises/decelerates in the first half of the stance 
phase and then falls/accelerates during the second half of the stance phase 
(Candrilli et al., 2007; Lamoreux, 1972; Lee and Farley, 1998, Thorstensson and 
Roberthson, 1987). Consequently, in the first half of the stance phase, kinetic energy 
is converted into gravitational potential energy (Cavagna et al., 1976; Cavagna and 
Franzetti, 1986), whereas in the second half of the stance phase, the opposite 
conversion occurs. Over the gait cycle, the CoM has a sinusoidal pattern in the 
vertical direction with two peaks occurring. The first vertical peak of the CoM occurs 
around 30% of the gait cycle during single-limb stance as the CoM is ‘vaulted’ over 
the straight stance limb in an inverted pendulum manner, while the second peak 
occurs around 80% of the gait cycle during the terminal mid-stance phase.  
Increasing the CoM displacement in a type of up and down ‘bobbing’ action leads to 
an increase in the CoW compared to a normal gait (Neptune et al., 2004; Massaad 
et al., 2007). Equally, if gait is manipulated to minimise or eliminate any vertical 
displacement of the CoM by walking in a ‘crouched’ style with very flexed limbs, 
there is an increase in the CoW compared to normal gait (Ortega et al., 2007; 
Massaad et al., 2007; Gordon et al., 2009). Hence, there appears to be an ‘optimum’ 
vertical displacement for the CoM in terms of its effect on the metabolic CoW, where 
deviations from this optimum seem inefficient in terms of energy cost.  
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Stride length also seems intrinsically linked to the CoM vertical displacement and the 
associated CoW. It has been shown that stride lengths greater than the optimal, 
increase the CoM vertical displacement and increase the CoW, while stride lengths 
lower than the optimal, reduce the vertical displacement of the CoM, but also 
increase the CoW (Gordon et al., 2009). Since it is known that diabetes patients take 
shorter steps compared to controls, it might be hypothesised that that this would 
reduce the vertical displacement of the CoM, thereby increasing the CoW. Because 
walking speed may be a confounding factor in the relationship between step length 
and CoM displacement, in the present study we choose to compare the CoM vertical 
displacement at matched walking speeds between patients with diabetes and 
controls. Therefore, this study examined the vertical displacement of the CoM while 
walking at a range of matched speeds between 0.6 and 1.6 m/s. We hypothesised 
that diabetes patients would have a reduced vertical CoM displacement that might 
explain our recent findings of a greater CoW, with a reduced step length being a 
potential factor underpinning the suggested CoM behaviour. 
 
MATERIALS AND METHODS 
Participants 
After receiving ethical approval from all relevant bodies, 67 participants gave written 
informed consent to participate in this study. All procedures in this study complied 
with the declaration of Helsinki. All participants were allocated into one of three 
groups: patients with diabetes and moderate-severe peripheral neuropathy (DPN, 
n=14, 14 men), patients with diabetes but no peripheral neuropathy (DM, n=22, 12 
men) and healthy controls without diabetes or peripheral neuropathy (Ctrl, n=31, 19 
men). The same participant cohort was examined to establish the metabolic CoW 
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and reported in references (Petrovic et al., 2016). The CoW was significantly higher 
particularly in the DPN group compared with controls and also in the DM group 
compared with controls, across a range of matched walking speeds. 
All participants were assessed to confirm they satisfied the inclusion criteria for each 
group. Major exclusion criteria for participation in the study included peripheral 
vascular disease, musculoskeletal injury or recent surgery affecting gait, any 
amputation other than 1 or 2 lesser toes and open foot ulcer. A random blood 
glucose test was performed in the Ctrl group to confirm the absence of diabetes (<7 
mmol/l) and the below neuropathy tests conducted to confirm the absence of 
neuropathy in the Controls. The majority of the DM and the DPN patients reported 
taking insulin, cholesterol-lowering medication and diabetes medication, while from 
the whole sample (including controls) only 2 people reported smoking.  
 
Assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify peripheral neuropathy in diabetic 
patients and to confirm the absence of neuropathy in healthy controls. Peripheral 
neuropathy was assessed by using the modified Neuropathy Disability Score 
(mNDS) and the vibration perception threshold (VPT). The mNDS is a combined 
score taken from tests measuring the patient’s ability to detect temperature, pain, 
vibration and the Achilles tendon reflex (Boulton, 2005). The VPT was assessed by 
placing the probe of the biothesiometer (Biomedical Instrument Co, Newbury, OH, 
USA) on the apex of the hallux and increasing the level of vibration until detected by 
the participant. Patients were defined as having moderate-to-severe neuropathy and 
classed as DPN if in either one or both of their feet they displayed either an mNDS 
score of ≥6 or a VPT of ≥25 V (or both). 
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Gait analysis 
Participants were asked to walk along a 10-metre walkway in the gait laboratory at a 
series of standardised speeds (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s). The standardised 
walking speeds were controlled by measuring the velocity of a marker attached to 
the sacrum after each trial from the motion analysis data and providing immediate 
feedback for participants as to whether they needed to walk more quickly or more 
slowly on the next trial to achieve the required speed. The participant's starting 
position was altered by the experimenter to ensure a ‘clean’ (i.e., no overlap outside 
the force platform) foot-strike on one or two of the force platforms (positioned in the 
middle of the walkway) per walking trial without alteration to their natural gait. 
Walking trials were repeated until at least three ‘clean’ foot contacts with the force 
platforms were made with each limb, for each walking speed condition. Kinematics 
were collected at 100 Hz using a 10-camera Vicon motion capture system (Vicon, 
Oxford, UK) positioned around the 10-meter walkway, tracking a full-body modified 
Plug-In-Gait marker set consisting of 54 markers. Where possible markers were 
placed directly onto the skin; to minimise movement artefacts resulting from loose 
clothing all participants wore tight-fitting shorts and tops. All participants wore 
specialist diabetic shoes (MedSurg, Darco, Raisting, Germany) with a neutral foot-
bed (no rocker bottom outsole), ensuring the diabetic patients walked with safe, 
appropriate footwear whilst minimising the effect of footwear by standardising across 
all participants.  
 
Centre of mass displacement 
Gait variables (stride length, step length and cadence, vertical displacement of the 
CoM) were calculated from the kinematic data using Visual 3D software. The vertical 
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displacement of the CoM was measured from the kinematic data using Visual 3D 
software (C-motion Inc., MD, USA). Motion data collected during gait analysis were 
processed, and Dempster’s segment parameter model (1955) was used to calculate 
mass distribution for each body segment, thereby allowing accurate calculation of 
the entire body centre of mass. The vertical displacement of the CoM was calculated 
as the maximum range of vertical displacement (minimum to maximum peak) of the 
CoM (Figure 2) during the whole gait cycle, using the mean of the three trials from 
each person. 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to assess 
between group differences. If the ANOVA was significant, a Fisher’s least significant 
difference (LSD) post-hoc test was used to test for differences between the diabetes 
groups (DM and DPN) and the control group. All values presented are means and 
standard deviation. Significance was set at p<0.05. The power analysis identified 
minimum group sizes of n=7, for an effect size 0.71 (β=0.1, α=1%). Analysis of 
covariance was used to assess the effect of body mass on CoM excursion. 
Pearson product-moment correlation coefficients were calculated at each walking 
speed (and all walking speeds combined) using data from participants in all three 
experimental groups to determine whether there was a significant correlation 
between the CoM vertical displacement and the cost of walking (previously published 
data on CoW, Petrovic et al., 2016). 
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RESULTS 
Participant characteristics  
There were significant differences between the groups in age, body mass and BMI, 
which were significantly greater in the DPN group (Table 1, p<0.01). 
 
Step length and cadence 
The DPN group displayed significantly shorter step lengths across all speeds 
compared to the Ctrl group (Table 2). The DPN group had significantly higher 
cadence across all speeds compared to the control group. 
 
Centre of mass displacement at different speeds 
Across all matched speeds there were no significant differences in the CoM vertical 
displacement between groups (Fig. 1; Table 3), neither when including a body mass 
as a covariate. 
Pearson’s correlations only reached significance at walking speeds of 0.8 and 1.6 
m/s, but the r values were consistently low across speeds ranging between -0.287 
and 0.262 (Table 4). When combining data for all participants, across all walking 
speeds Pearson’s correlation failed to reach significance, with an r value of -0.08 
(Table 4, Figure 3). 
 
DISCUSSION 
This study has shown for the first time that the vertical displacement of the CoM 
during walking is not different between diabetes patients with and without diabetic 
peripheral neuropathy compared to controls across a range of matched speeds (Fig. 
1) and is therefore unlikely to be a factor in itself that contributes towards the 
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increased CoW observed recently(Petrovic et al., 2016) on the same data set in 
people with diabetic peripheral neuropathy (at 1.2 m/s: Ctrl: 2.18 (SD: 0.67), DM: 
2.20 (0.81), DPN: 2.35 (1.76) J·kg1·m1; p>0.05). Furthermore, the relationship 
between the CoM and CoW was very weak across all walking speeds (Table 4, 
Figure 3), indicating no clear link between these two variables across participant 
groups in the present study.  
It has previously been shown that stride lengths shorter and longer than the optimum 
lead to reduced and increased CoM displacements, respectively, but increasing the 
metabolic CoW in both situations (Gordon et al., 2009). In this previous study, 
participants increased their metabolic cost when they reduced their vertical CoM 
movement by taking shorter strides. Participants also expended more metabolic 
energy when they walked with a greater stride length than their preferred stride 
length. Previous work (Donelan et al., 2002) has shown that as stride length 
increases, metabolic energy expenditure and mechanical work performed on the 
CoM also increase. This is not caused by CoM displacement per se but rather by the 
additional negative work performed to redirect the CoM velocity during step-to-step 
transitions and by positive work to restore the energy lost. Although we did find 
consistently shorter step lengths across matched walking speeds in patients with 
diabetes and particularly those with diabetic peripheral neuropathy compared to 
controls, this did not alter the vertical displacement of the CoM compared to controls 
(Fig. 1).  
The lack of effect of stride shortening on the CoM in the present study might be due 
to the fact that people with diabetes and diabetic peripheral neuropathy have 
adapted to a different optimal step length, which is consistently shorter compared to 
controls across the range of walking speeds examined. Alternatively, they could 
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have adopted a different step length based on the total metabolic CoW rather than 
the cost associated with CoM displacement. Consistent with the shorter steps taken 
by both diabetes groups compared to controls, was the higher cadence required to 
meet the prescribed matched walking speeds by the diabetes patients (Table 2). An 
increased cadence in the diabetes groups would require greater internal work from 
the muscles to move the legs during walking (Minetti et al., 1994). Although we have 
previously found (Petrovic et al, 2016) the joint work developed during a single 
stance phase to be lower in patients with diabetes and even more so in those with 
diabetic peripheral neuropathy, this would be repeated more often over a given 
distance in diabetes patients because of a higher cadence. Therefore, a higher 
cadence for any given walking speed could explain the higher CoW previously 
reported in patients with diabetes and those with diabetic peripheral neuropathy 
through greater cumulative joint work (Petrovic et al., 2016). 
In the absence of differences in the CoM vertical displacement, another possible 
explanation for the higher CoW previously reported in diabetes patients is that they 
might be producing greater muscle force without performing as much joint work per 
stance phase. This would be consistent with previous reports from walking with a 
‘crouched gait’ by excessively flexing the joints (Massaad et al., 2007; Ortega et al., 
2007). Diabetes patients were observed to walk with shorter steps, which is known to 
be achieved by greater flexion in the lower limb joints. This likely gives rise to higher 
muscle forces to sustain the more flexed joint positions as previously observed 
(Sasaki et al., 2009) and consequently a higher metabolic CoW. Therefore, the 
effective mechanical advantage (muscle force moment arm/ground reaction force 
moment arm) may be less favourable in diabetic patients (Petrovic et al., 2017), 
which would mean that more muscle force would be required to overcome the 
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moment of the ground reaction force – hence higher CoW. This factor may also 
explain why diabetes patients have adopted an “optimum” CoM displacement 
(meaning unaltered compared to controls) per stride length as a strategy to minimise 
CoW. Gordon et al. (2009) presented in their study a manipulation of step length 
above and below the optimal and found that the CoM vertical displacement 
increases and decreases over that observed at the self-selected step length. Both of 
these situations were associated with a higher metabolic CoW compared to that 
observed at self-selected step length, suggesting an optimal vertical displacement of 
the CoM where energy cost is minimised. People who are at higher risk of falls have 
been shown to take shorter steps (Karamanidis et al., 2008; Schillings et al., 2005) 
as part of a more cautious strategy to walking, which could be one of a number of 
potential factors causing them to walk with shorter steps. Another potential reason 
could relate to reduced ankle range of movement, reduced Achilles tendon 
elongation and increased Achilles tendon stiffness during walking as we have 
recently shown (Petrovic et al, 2018). 
Other factors contributing to an increased metabolic CoW in patients with diabetes 
and diabetic peripheral neuropathy could include increased muscle co-activation, 
which has been shown in older adults without diabetes (Cronin et al., 2010, Mian et 
al., 2007) and an increased Achilles tendon stiffness (Petrovic et al., 2018). Indeed, 
we have recently shown how Achilles tendon stiffness is higher in people with 
diabetes and particularly those with diabetic peripheral neuropathy compared to 
controls during walking (Petrovic et al., 2018). An increased Achilles tendon stiffness 
would reduce the elastic energy stored from this long tendon during walking, 
requiring a relatively greater energy contribution from the plantar flexor muscles, 
increasing the metabolic CoW. 
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To the best of our knowledge this is the first study that has investigated the CoM 
displacement during walking in a diabetic patient population. It could be considered 
as a limitation of the present study that body mass was significantly different 
between groups. However, the higher body mass of patients with diabetes 
(especially those with DPN) is a well-known characteristic of this population 
described in the literature (Ijzerman et al., 2011; Jor’dan et al., 2014) and is unlikely 
to have directly affected the CoM vertical displacement. If anything, it might be 
expected that increased body mass might reduce the extent to which the CoM is 
displaced, but this was not found in the present study indicating that group 
differences in body mass did not influence the present results. Although only a mean 
of 10 years difference, patients in the DPN group were significantly older than 
controls (66 to 56 years, respectively), which might be considered a confounding 
factor for some of the variables examined. 
We have shown that there are no differences in the vertical displacement of the CoM 
in patients with diabetes compared with controls when walking speed is matched and 
no relationship between the CoM vertical displacement and the CoW. The higher 
CoW in patients with diabetes may not be explained by the vertical CoM 
displacement, but rather may be more related to shorter step lengths, increased 
cadence and the associated increased internal work and higher muscles forces 
developed by walking with more flexed joints. 
 
Conflict of interest statement 
The authors confirm that they do not have any financial or personal relationships with 
other people or organisations that could inappropriately influence this manuscript. 
 
  
14 
 
Acknowledgements  
This study was funded by the European Commission through MOVE-AGE, an 
Erasmus Mundus Joint Doctorate programme. 
 
REFERENCES 
 
Abate, M., Schiavone, C., Di Carlo, L., Salini, V., 2012. Achilles tendon and 
plantar fascia in recently diagnosed type II diabetes: role of body mass index. 
Clin Rheumatol 31: 1109–1113. 
 
Alexander, R.M., 1991. Energy-saving mechanisms in walking and running. J Exp 
Biol 160: 55–69. 
 
Andersen, H., 2012. Motor dysfunction in diabetes. Diabetes Metab Res Rev 28: 
89–92. 
 
Boulton, A.J.M., 2005. Management of Diabetic Peripheral Neuropathy. Clin Diab 
23: 9–15. 
 
Brown, S.J., Handsaker, J.C., Bowling, F.L., Maganaris, C.N., Boulton, A.J.M., 
Reeves, N.D., 2014. Do patients with diabetic neuropathy use a higher proportion 
of their maximum strength when walking? J Biomech 47: 3639–3644. 
 
Brown, S.J., Handsaker, J.C., Bowling, F.L., Boulton, A.J.M., Reeves, N.D., 2015. 
Diabetic peripheral neuropathy compromises balance during daily activities. 
Diabetes Care 38 (6): 1116–1122. 
 
Cappozzo, A., 1981. Analysis of the linear displacement of the head and trunk 
during walking at different speeds. J Biomech 14: 411–25. 
 
Candrilli, S.D., Davis, K.L., Kan, H.J., Lucero, M.A., Rousculp, M.D., 2007. 
Prevalence and the associated burden of illness of symptoms of diabetic 
peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 21: 
306–314. 
 
Cavagna, G.A., Thys, H., Zamboni, A., 1976. The sources of external work in 
level walking and running. J Physiol 262: 639–657. 
 
Cavagna, G.A., Franzetti, P., 1986. The determinants of the step frequency in 
walking in humans. J Physiol 373: 235–242. 
 
Chiles, N.S., Phillips, C.L., Volpato, S., Bandinelli, S., Ferrucci, L., Guralnik, J.M., 
Patel, K.V., 2014. Diabetes, Peripheral Neuropathy and Lower Extremity 
Function. J Diabetes Complicat 28: 91–95. 
 
Cronin, N.J., Peltonen, J., Ishikawa, M., Komi, P.V., Avela, J., Sinkjaer, T., Voigt, 
  
15 
 
M., 2010. Achilles tendon length changes during walking in long-term diabetic 
patients. Clin Biomech 25: 476–82. 
 
Dempster WT, 1955. Space requirements of the seated operator: geometrical, 
kinematic, and mechanical aspects of the body with special reference to the limbs 
[Internet], Available from http://books.google.co.uk/books/about/ 
Space_Requirements_of_the_Seated_Operato 
html?id=Ks1pAAAAMAAJ&redir_esc=y. Accessed 30 October 2018 
 
Donelan, J.M., Kram, R., Kuo, A.D., 2002. Mechanical work for step-to-step 
transitions is a major determinant of the metabolic cost of human walking. J Exp 
Biol 205: 3717–3727. 
 
Gomes, A.A., Onodera, A.N., Otuzi, M.E.I., Pripas, D., Mezzarane, R.A., Sacco 
.I.C.N., 2001. Electromyography and kinematic changes of gait cycle at different 
cadences in diabetic neuropathic individuals. Diabet Neuropathic Gait Muscle 
Nerve 2: 258–268. 
 
Gordon, K.E., Ferris, D.P., Kuo, A.D., 2009. Metabolic and mechanical energy 
costs of reducing vertical center of mass movement during gait. Arch Phys Med 
Rehabil 90: 136–144. 
 
International Diabetes Federation. (2013). IDF Diabetes Atlas (6th ed.) Brussels, 
Belgium. Retrieved from http://www.idf.org/diabetesatlas 
 
Ijzerman, T.H., Schaper, N.C., Melai, T., Meijer, K., Willems, P.J.B., Savelberg, 
H.H.C.M., 2011. Lower extremity muscle strength is reduced in people with type 
2 diabetes, with and without polyneuropathy, and is associated with impaired 
mobility and reduced quality of life. Diabetes Res Clin Pr  95: 345–351. 
 
Jor’dan, A.J., Manor, B., Novak, V., 2014. Slow gait speed - an indicator of lower 
cerebral vasoreactivity in type 2 diabetes mellitus. FNAGI 6: 1-9. 
 
Karamanidis, K., Arampatzis, A., Mademli, L., 2008. Age-related deficit in 
dynamic stability control after forward falls is affected by muscle strength and 
tendon stiffness. J Electromyogr Kinesiol 18: 980–989. 
 
Ko, S.U., Stenholm, S., Chia, C.W., Simonsick, E.M., Ferrucci, L., 2011. Gait 
pattern alterations in older adults associated with type 2 diabetes in the absence 
of peripheral neuropathy - Results from the Baltimore Longitudinal Study of 
Aging. Gait Posture 34: 548–552. 
 
Lamoreux, L.W., 1972. Kinematic measurements of walking. Mech Eng 94: 64–
67. 
 
Lee, C.R., Farley, C.T., 1988. Determinants of the center of mass trajectory in 
human walking and running. J Exp Biol 201: 2935–2944. 
 
Martinelli, A.R., Mantovani, A.M., Nozabieli, A.J.L., Ferreira, D.M.A., Barela, J.A., 
Camargo, M.R. De, Fregonesi, C.E.P.T., 2013. Muscle strength and ankle 
  
16 
 
mobility for the gait parameters in diabetic neuropathies. Foot 23: 17–21. 
 
Massaad, F., Lejeune, T.M., Detrembleur, C., 2007. The up and down bobbing of 
human walking: a compromise between muscle work and efficiency. J Physiol 
582: 789–799. 
 
Menz, H.B., Lord, S.R., George, R., Fitzpatrick, R.C., 2004. Walking stability and 
sensorimotor function in older people with diabetic peripheral neuropathy. Arch 
Phys Med Rehabil 85: 245–252. 
 
Mian, O.S., Thom, J.M., Ardigò, L.P., Minetti, A.E., Narici, M.V., 2007. 
Gastrocnemius muscle-tendon behaviour during walking in young and older 
adults. Acta Physiologica, 189: 57–65.  
 
Minetti, A.E., Ardigò, L.P., Saibene, F., 1994. The transition between walking and 
running in humans: metabolic and mechanical aspects at different gradients. Acta 
Physiol Scand 150: 315-323. 
 
Neptune, R.R., Zajac, F.E., Kautz, S.A., 2004. Muscle mechanical work 
requirements during normal walking: the energetic cost of raising the body’s 
center-of-mass is significant. J Biomech 37: 817–825. 
 
Ortega, J.D., Farley, C.T., 2007. Individual limb work does not explain the greater 
metabolic cost of walking in elderly adults. J Appl Physiol 102: 2266–2273. 
 
Petrovic, M., Deschamps, K., Verschueren, S.M., Bowling, F.L., Maganaris, C.N., 
Boulton, A.J.M., Reeves, N.D., 2016. Is the metabolic cost of walking higher in 
people with diabetes? J Appl Physiol 120: 55–62. 
 
Petrovic, M., Deschamps, K., Verschueren, S.M., Bowling, F.L., Maganaris, C.N., 
Boulton, A.J.M., Reeves, N.D., 2017. Altered leverage around the ankle in people 
with diabetes: A natural strategy to modify the muscular contribution during 
walking? Gait Posture 57: 85-90. 
 
Petrovic, M., Maganaris, C.N., Deschamps, K., Verschueren, S.M., Bowling, F.L., 
Boulton, A.J.M., Reeves, N.D., 2018. Altered Achilles tendon function during 
walking in people with diabetic neuropathy: implications for metabolic energy 
saving. J Appl Physiol 24: 1333-1340. 
 
Raspovic, A., 2013. Gait characteristics of people with diabetes-related peripheral 
neuropathy, with and without a history of ulceration. Gait Posture 38: 723–728. 
 
Sacco, I.C., Amadio, A.C., 2002. A study of biomechanical parameters in gait 
analysis and sensitive cronaxie of diabetic neuropathic patients. Clin Biomech 15: 
196–202. 
 
Sasaki, K., Neptune, R.R., Kautz, S., 2009. The relationships between muscle, 
external, internal and joint mechanical work during normal walking. J Exp Biol 
212: 738–744. 
 
  
17 
 
Sawacha, Z., Gabriella, G., Cristoferi, G., Guiotto, A., Avogaro, A., Cobelli, C., 
2009. Diabetic gait and posture abnormalities: a biomechanical investigation 
through three dimensional gait analysis. Clin Biomech 24: 722–728. 
 
Schillings, A.M., Mulder, T., Duysens, J., 2005. Stumbling over obstacles in older 
adults compared to young adults. J Neurophysiol 94: 1158–1168. 
 
Thorstensson, A., Roberthson, H., 1987. Adaptations to changing speed in 
human locomotion. Acta Physiol Scand 131: 211–214. 
 
 
 
The authors confirm that they do not have any financial or personal relationships with 
other people or organisations that could inappropriately influence this manuscript. 
 
*Conflict of Interest Statement
